Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study

IntroductionClinical remission as a multicomponent treatment goal in severe asthma is being explored in clinical practice. This post hoc analysis used data from the REDES study to assess the proportion of patients with severe eosinophilic asthma achieving our multicomponent definitions of clinical r...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Ian Pavord, Frances Gardiner, Liam G. Heaney, Christian Domingo, Robert G. Price, Alison Pullan, John Oppenheimer, Guy Brusselle, Hiroyuki Nagase, Geoffrey Chupp, Emilio Pizzichini, David Bañas-Conejero, Peter Howarth
Μορφή:	Άρθρο
Γλώσσα:	English
Έκδοση:	Frontiers Media S.A. 2023-04-01
Σειρά:	Frontiers in Immunology
Θέματα:	severe asthma remission clinical outcomes real-world eosinophil biology mepolizumab
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1150162/full

Παρόμοια τεκμήρια

A Case of Eosinophilic Gastroenteritis Remission Achieved Steroid-Free With Mepolizumab
ανά: Yuki Hirata, κ.ά.
Έκδοση: (2022-01-01)

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study
ανά: Masanobu Ueno, κ.ά.
Έκδοση: (2022-06-01)

Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
ανά: Mkorombindo T, κ.ά.
Έκδοση: (2019-08-01)

Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab
ανά: Diego Bagnasco, κ.ά.
Έκδοση: (2024-04-01)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
ανά: Steven W. Yancey, κ.ά.
Έκδοση: (2019-09-01)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
ανά: Haldar P
Έκδοση: (2017-06-01)

Mepolizumab-responsive recurrent eosinophilic eruption without peripheral eosinophilia
ανά: Nina B. Curkovic, MD, κ.ά.
Έκδοση: (2024-11-01)

The clinical question of mepolizumab in the long-term treatment of idiopathic chronic eosinophilic pneumonia; how long should we use mepolizumab?
ανά: Masamitsu Hamakawa, κ.ά.
Έκδοση: (2024-01-01)

Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis
ανά: Masanobu Ueno, κ.ά.
Έκδοση: (2021-03-01)

Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
ανά: Ryota Otoshi, κ.ά.
Έκδοση: (2020-03-01)

Clinical efficacy of mepolizumab in the treatment of severe eosinophilic asthma in children
ανά: V. N. Drozdov, κ.ά.
Έκδοση: (2020-11-01)

Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis
ανά: Giuseppe A. Ramirez, κ.ά.
Έκδοση: (2022-12-01)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
ανά: Pelaia C, κ.ά.
Έκδοση: (2017-10-01)

May mepolizumab used in asthma correct subfertility?
ανά: Guzin Ozden, κ.ά.
Έκδοση: (2021-01-01)

Allergic bronchopulmonary aspergillosis complicated by eosinophilic chronic rhinosinusitis successfully treated with mepolizumab
ανά: Nobuhiro Matsumoto, κ.ά.
Έκδοση: (2019-10-01)

Experience with mepolizumab in adults with severe eosinophilic asthma: a case series from India
ανά: Venkata Nagarjuna Maturu, κ.ά.
Έκδοση: (2021-08-01)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
ανά: Takanori Numata, κ.ά.
Έκδοση: (2019-10-01)

Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma
ανά: Jolita Palacionyte, κ.ά.
Έκδοση: (2024-06-01)

Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
ανά: Alistair Cook, κ.ά.
Έκδοση: (2021-05-01)

Predictors of the enhanced response to mepolizumab treatment for severe eosinophilic asthma: A retrospective, long-term study
ανά: Takanori Numata, κ.ά.
Έκδοση: (2020-01-01)

Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study
ανά: Kenneth R. Chapman, κ.ά.
Έκδοση: (2024-02-01)

Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
ανά: I. J. Pouliquen, κ.ά.
Έκδοση: (2017-11-01)

Mepolizumab para el tratamiento de asma grave eosinofílica
ανά: Armando Partida-Gaytán, κ.ά.
Έκδοση: (2021-01-01)

When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report
ανά: M. Sabbe, κ.ά.
Έκδοση: (2024-01-01)

Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan
ανά: Takashi Yamane, κ.ά.
Έκδοση: (2023-06-01)

Mepolizumab Therapy for Recalcitrant Eosinophilic Annular Erythema in an Adult: A Case Report and Review of Treatment Options
ανά: Magdalena Żychowska, κ.ά.
Έκδοση: (2020-06-01)

Case Report: Mepolizumab in the treatment of idiopathic chronic eosinophilic pneumonia [version 3; peer review: 2 approved]
ανά: Moetemri Zied, κ.ά.
Έκδοση: (2023-09-01)

Real-world outcomes of mepolizumab treatment in severe eosinophilic asthma patients - retrospective cohort study in Slovakia
ανά: Milos Jesenak, κ.ά.
Έκδοση: (2023-09-01)

Idiopathic hypereosinophilic syndrome with eosinophilic cellulitis-like cutaneous involvement treated with mepolizumab and dapsone
ανά: Madeleine Lachance, MD, κ.ά.
Έκδοση: (2022-04-01)

Combination effect of Mepolizumab and Endobronchial Watanabe Spigot (EWS) in drug‐induced eosinophilic pneumonia complicated by refractory pneumothorax
ανά: Nana Ayame, κ.ά.
Έκδοση: (2024-09-01)

Switching from omalizumab to mepolizumab therapy improved extra‐pulmonary abdominal and cutaneous vasculitis symptoms in a patient with eosinophilic granulomatosis with polyangiitis
ανά: Yu‐Hsuan Chen, κ.ά.
Έκδοση: (2022-01-01)

Role of mepolizumab in severe allergic asthma with vocal cord polyp
ανά: Azmat Karim, κ.ά.
Έκδοση: (2022-01-01)

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series
ανά: Carlo Lombardi, κ.ά.
Έκδοση: (2024-07-01)

Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions
ανά: Peter G. Gibson, κ.ά.
Έκδοση: (2021-06-01)

Severe asthma remaining well‐controlled after mepolizumab discontinuation: A case report and literature review
ανά: Takahiro Matsuyama, κ.ά.
Έκδοση: (2023-06-01)

Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis
ανά: Nami Masumoto, κ.ά.
Έκδοση: (2023-05-01)

Severe eosinophilic bronchial asthma: new therapeutic options
ανά: N. M. Nenasheva
Έκδοση: (2018-10-01)

Low-dose anti-IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance
ανά: Marco Caminati, κ.ά.
Έκδοση: (2023-09-01)

Gastrointestinal Involvement of Eosinophilic Granulomatosis with Polyangiitis with Histological Evidence of Treatment Response
ανά: Mark Lai, κ.ά.
Έκδοση: (2023-03-01)

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma
ανά: Manuel David Gil-Sierra, κ.ά.
Έκδοση: (2019-11-01)